Director Leon Recanati Buys $292K of Evogene Stock at $0.635
EVGN sits 62% above its 52-week low of $0.37 on light trading volume (0.3× avg).
Summary
Director Leon Recanati bought $292,100 worth of Evogene shares at $0.635, increasing his stake to 1.34 million shares.
Key Events · Ownership and Investor Activity · EVGN
-
Director Buys $292K in Open Market
On August 11, 2026, Leon Recanati purchased 460,000 ordinary shares at $0.635 per share, for a total of $292,100.
-
Stake Increases to 1.34M Shares
Following the purchase, Recanati directly owns 1,343,886 shares, up from 883,886 shares.
-
Purchase Amid Proxy Fight
The buy comes as activist shareholders seek to replace most of the board, and the company has an active ATM offering.
-
Transaction Represents ~3% of Market Cap
The $292,100 purchase is significant relative to Evogene's $9.7 million market capitalization.
Analysis · EVGN · Industrial Applications And Services
On August 11, 2026, Director Leon Recanati bought 460,000 shares at $0.635 per share, totaling $292,100. This substantial open-market purchase by a board member represents about 3% of the company's market cap. It comes amid a proxy fight with activist shareholders and a heavily dilutive ATM offering, suggesting the director is putting personal capital behind the company's defense.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVGN was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.